Biotech Values

[DewDiligence]

GRAY IPOs 6.47M* shares @$16.00:

https://www.globenewswire.com/news-release/2020/09/25/2099066/0/en/Graybug-Vision-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic diseases of the retina and optic nerve.

The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for up to six months and potentially longer, improving patient compliance, reducing healthcare burdens and ultimately delivering better clinical outcomes.

Graybug’s lead product candidate, GB-102, a microparticle depot formulation of sunitinib malate, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration, with a six-month dosing regimen.

Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection.

Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California.

A safe and effective drug with a six-month (or longer) dosing interval in wet-amd and open-angle glaucoma would be a major advance in patient convenience and satisfaction. The business proposition is similar to what RVNC is doing with Daxi.

*Assuming exercise of underwriter’s option.